A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
about
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
A preclinical evaluation of th ...... e to trastuzumab or lapatinib.
@en
A preclinical evaluation of th ...... e to trastuzumab or lapatinib.
@nl
type
label
A preclinical evaluation of th ...... e to trastuzumab or lapatinib.
@en
A preclinical evaluation of th ...... e to trastuzumab or lapatinib.
@nl
prefLabel
A preclinical evaluation of th ...... e to trastuzumab or lapatinib.
@en
A preclinical evaluation of th ...... e to trastuzumab or lapatinib.
@nl
P2093
P2860
P356
P1433
P1476
A preclinical evaluation of th ...... e to trastuzumab or lapatinib.
@en
P2093
Aoife Carr
Bryan T Hennessy
Clare Morgan
Frankie Holmes
John O'Shea
Joyce O'Shaughnessy
Lance Liotta
Malgorzata Milewska
Mattia Cremona
Naomi Elster
P2860
P304
85120-85135
P356
10.18632/ONCOTARGET.19461
P407
P577
2017-07-22T00:00:00Z